Eptifibatide Side Effects: Safety Signals and Warnings
Eptifibatide safety concerns are compound-specific. The main listed side effects are Bleeding (major and minor), Thrombocytopenia, and Hypotension. The main warning signals are Contraindicated with active internal bleeding or recent surgery, Severe thrombocytopenia (<100,000/mm3) - discontinue immediately, and Renal dose adjustment required (CrCl <50 mL/min).
Direct Answer
Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Acute coronary syndrome management, PCI antiplatelet therapy, GP IIb/IIIa inhibition research
Reported Side Effects
- Bleeding (major and minor)
- Thrombocytopenia
- Hypotension
- Back pain
- Nausea
Warnings
- Contraindicated with active internal bleeding or recent surgery
- Severe thrombocytopenia (<100,000/mm3) - discontinue immediately
- Renal dose adjustment required (CrCl <50 mL/min)
- Avoid in patients with history of hemorrhagic stroke
Known or Plausible Interactions
- Heparin (co-administered but increases bleeding risk)
- Thrombolytics (significantly increased bleeding)
- Other antiplatelet agents (clopidogrel - additive effect)
- NSAIDs (increased GI bleeding risk)
Regulatory Context
FDA-approved for acute coronary syndrome and percutaneous coronary intervention. Available by prescription for hospital use only. Marketed as Integrilin by Merck.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Acute Coronary Syndrome (Level A), PCI Outcomes (Level A), and Bleeding Risk (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Eptifibatide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/eptifibatide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.